Clinical Trial

Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This Phase 2 study evaluates the efficacy and safety of sequential treatment with percutaneous hepatic perfusion (PHP) using melphalan/HDS followed by tebentafusp in patients with metastatic uveal melanoma (mUM) with isolated liver metastases. The rationale is that PHP enhances antigen release and immunomodulation, potentially sensitizing tumors to tebentafusp in HLA-A\*02:01-positive patients.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-01.
Trial Details
NCT Number NCT07276386
Lead Sponsor H. Lee Moffitt Cancer Center and Research Institute
Collaborators: Delcath Systems Inc.
Conditions Metastatic Uveal Melanoma
Enrollment 18 participants
Start Date 2025-12-31
Primary Completion 2030-12 (estimated)
Study Completion 2030-12 (estimated)
Updated on ClinicalTrials.gov 2026-03-31